EP2828218

UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Application Number
EP13764186A
Filing Date
Mar 15, 2013
Status
Granted And Under Opposition
Jul 3, 2020
Grant Date
Apr 7, 2021
External Links
Slate, Register

Biblio Summary

The patent EP2828218B9 was granted on Apr 7, 2021 by University Of Washington Through Its Center For Commercialization The patent is currently Granted And Under Opposition.

The table below shows 3 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEWIS SILKIN LLPMay 5, 2021 N.A.
MARGARET DIXON LIMITEDMay 5, 2021 N.A.
WITHERS & ROGERS LLPMay 4, 2021 N.A.

The table below shows the patents of University Of Washington Through Its Center For Commercialization that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2838548Hla Class Ii Deficient Cells, Hla Class I Deficient Cells Capable Of Expressing Hla Class Ii Proteins, And Uses ThereofJul 19, 20232
EP2699593Beta-2 Microglobulin-Deficient CellsNov 4, 20201